This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Le Bras, M. Articles by Brenner, C. Search for Related Content PubMed PubMed Citation Articles by Le Bras, M. Articles by Brenner, C.

Chemosensitization by Knockdown of Adenine Nucleotide Translocase-2

¹ Centre National de la Reserche Scientifique UMR 8159, Université de Versailles/St. Quentin, Versailles, France; ² Theraptosis, Pasteur Biotop, Institut Pasteur, Paris, France; ³ Centre National de la Reserche Scientifique UMR 8125, Institute Gustave Roussy, Villejuif, France

Requests for reprints: Catherine Brenner, Centre National de la Reserche Scientifique UMR 8159, Université de Versailles/St. Quentin, 45 Avenue des Etats-Unis, 78035 Versailles, France. Phone: 33-1-39-25-45-52; Fax: 33-1-39-25-45-72; E-mail: cbrenner{at}genetique.uvsq.fr.

Mitochondrial membrane permeabilization (MMP) is a rate-limiting step of apoptosis, including in anticancer chemotherapy. Adenine nucleotide translocase (ANT) mediates the exchange of ADP and ATP on the inner mitochondrial membrane in healthy cells. In addition, ANT can cooperate with Bax to form a lethal pore during apoptosis. Humans possess four distinct ANT isoforms, encoded by four genes, whose transcription depends on the cell type, developmental stage, cell proliferation, and hormone status. Here, we show that the ANT2 gene is up-regulated in several hormone-dependent cancers. Knockdown of ANT2 by RNA interference induced no major changes in the aspect of the mitochondrial network or cell cycle but provoked minor increase in mitochondrial transmembrane potential and reactive oxygen species level and reduced intracellular ATP concentration without affecting glycolysis. At expression and functional levels, ANT2 depletion was not compensated by other ANT isoforms. Most importantly, ANT2, but not ANT1, silencing facilitated MMP induction by lonidamine, a mitochondrion-targeted antitumor compound already used in clinical studies for breast, ovarian, glioma, and lung cancer as well as prostate adenoma. The combination of ANT2 knockdown with lonidamine induced apoptosis irrespective of the Bcl-2 status. These data identify ANT2 as an endogenous inhibitor of MMP and suggest that its selective inhibition could constitute a promising strategy of chemosensitization. (Cancer Res 2006; 66(18): 9143-52)

This article has been cited by other articles:

				Q. Shen, F. Qin, Z. Gao, J. Cui, H. Xiao, Z. Xu, and C. Yang Adenine Nucleotide Translocator Cooperates with Core Cell Death Machinery To Promote Apoptosis in Caenorhabditis elegans Mol. Cell. Biol., July 15, 2009; 29(14): 3881 - 3893. [Abstract] [Full Text] [PDF]

				J. Montero, A. Morales, L. Llacuna, J. M. Lluis, O. Terrones, G. Basanez, B. Antonsson, J. Prieto, C. Garcia-Ruiz, A. Colell, et al. Mitochondrial Cholesterol Contributes to Chemotherapy Resistance in Hepatocellular Carcinoma Cancer Res., July 1, 2008; 68(13): 5246 - 5256. [Abstract] [Full Text] [PDF]